SCHEMBL25108924

SCHEMBL25108924

CCN1CCN(c2ccc(CNCCOCCOCCCC(C)C)cc2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.40
▸ RAD52 P43351 3/20 0.40
▸ MAPT P10636 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ GAA P10253 2/20 0.40
▸ GFER P55789 1/20 0.40
▸ CHRNA7 P36544 1/20 0.39
▸ DRD2 P14416 1/20 0.36
▸ DRD4 P21917 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ PAX8 Q06710 1/20 0.34
▸ TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22790760 0.88 L3MBTL1 (0.35) KDM4ERAD52MAPTSMN1; SMN2GAA
SCHEMBL24513989 0.88 KDM4E (0.41) KDM4ERAD52MAPTSMN1; SMN2GAA
SCHEMBL25109733 0.86 NPC1 (0.45) KDM4ERAD52MAPTSMN1; SMN2GAA
SCHEMBL25481170 0.85 KDM4E (0.34) KDM4ERAD52MAPTSMN1; SMN2GAA
SCHEMBL25481136 0.84 L3MBTL1 (0.34) KDM4ERAD52MAPTSMN1; SMN2GAA
SCHEMBL25110212 0.82 KDM4E (0.42) KDM4EMAPTSMN1; SMN2THRBTDP1
SCHEMBL24514674 0.80 NCF1 (0.45) KDM4EGAATHRBTDP1KMT2A
SCHEMBL22793929 0.80 KDM4E (0.42) KDM4ERAD52MAPTSMN1; SMN2GAA
SCHEMBL25110291 0.79 KDM4E (0.37) KDM4ERAD52MAPTSMN1; SMN2GAA
SCHEMBL24513990 0.79 KDM4E (0.41) KDM4EMAPTSMN1; SMN2THRBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCB1, SMARCE1 KDM4E 624/4885RAD52 669/4885MAPT 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback